Skip to main content
. 2022 Sep 15;13:5415. doi: 10.1038/s41467-022-32905-w

Fig. 3. SIRT6 depletion protects against Dex-induced reduction in myotube diameter.

Fig. 3

a Western blot (left) and relative quantification (right) to confirm RNAi-mediated depletion of SIRT6 in primary myotube transfected with control siRNA or siRNA targeting SIRT6. n = 6. b Representative confocal images depicting fiber diameter upon SIRT6 depletion in primary myotubes treated with Dex. Myotubes were stained red using an antibody against myomesin, Scale bar = 50 µm. c Quantification of fiber diameter upon SIRT6 depletion in primary myotubes described in b. n = 9. d Representative confocal images of MuRF-1/2/3 or Atrogin-1 levels upon SIRT6 depletion in primary myotubes treated with Dex. MuRF-1/2/3 or Atrogin-1 were stained in red and myomesin in green. Scale bar = 50 µm. e MuRF-1/2/3 or Atrogin-1 fluorescence intensity in myotubes described in d. MuRF-1/2/3 (Control-Veh n = 250, Control-Dex n = 204, SIRT6-KD-Veh n = 187, SIRT6-KD-Dex n = 254), Atrogin-1 (Control-Veh n = 173, Control-Dex n = 131, SIRT6-KD-Veh n = 96, SIRT6-KD-Dex n = 92). f Western blot (left) and relative quantification (right) of protein synthesis in Dex or Veh treated SIRT6 depleted myotubes. Control-Veh n = 7, Control-Dex n = 6, SIRT6-KD-Veh n = 8, SIRT6-KD-Dex n = 7. Data presented as mean ± s.d., *p < 0.05, ns not significant. Two-tailed unpaired Student’s t-test was used for statistical analysis (a), two-way ANOVA with Bonferroni post hoc test (c, e, f). Source data are provided as a Source Data file.